[ by | Apr 18, 2012 10:23 am | Comments Off ]
Single-Pill Treatment Is Associated With Better Treatment Adherence In People With HIV

Results from a recent study suggest that people with HIV whose antiretroviral regimen is taken as a single pill per day have better treatment adherence and a lower risk of hospitalization compared with people whose regimens consist of three or more pills per day.

“This study found that patients who receive [antiretroviral therapy] as a single pill per day are significantly more likely to be highly adherent to therapy. Furthermore, receiving a single pill per day was associated with a lower risk of hospitalization when compared with receiving multiple pills per day,” wrote the study authors.

“Although this study could not assess causality, it did show that receiving [antiretroviral therapy] as a single pill per day was associated with potential clinical and economic benefits,” they added.

According to the study investigators, high, sustained treatment adherence is necessary throughout a patient’s lifetime for optimal treatment outcomes. Studies in patients …

Read the full story »
[ by | Apr 11, 2012 10:13 am | Comments Off ]
Metabolic Syndrome Differs Between Treated And Untreated People With HIV

Results from a recent Italian study indicate that people with HIV, both on and off antiretroviral therapy, have similar low rates of metabolic syndrome, a condition which includes pre-diabetes, obesity, and other features.

However, the results also indicated that the symptoms of metabolic syndrome were different in previously untreated patients versus those in patients receiving highly active antiretroviral therapy.

Based on the results, the study investigators concluded that people with HIV who are on antiretroviral therapy develop metabolic syndrome differently than people who have not been treated.

According to the …

Read the full story »
[ by | Apr 4, 2012 5:58 am | Comments Off ]
Stimulation Of HIV-Specific Immune Cells Is Necessary To Eliminate Latent HIV

Results from a recent study suggest that stimulation of immune cells that specifically target HIV is necessary to eradicate latent HIV. The results also suggest that simply activating latent HIV is not sufficient to eliminate the virus from the body.

Based on the results, the researchers suggested that boosting immune responses through vaccination, followed by reactivation of latent HIV, may be an effective strategy for eradicating HIV.

Latent HIV is HIV that is not actively replicating. Since antiretroviral drugs usually work by blocking replication, they do not work on latent …

Read the full story »
[ by | Mar 30, 2012 9:11 am | One Comment ]
Investigational Therapeutic Vaccine May Boost Immune Function In People With HIV (CROI 2012)

Results from a recent study suggest that a new investigational therapeutic vaccine may boost immune system function in people with HIV, leading to a lower HIV rebound upon interruption of antiretroviral therapy.

Results from the study were presented earlier this month at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

Therapeutic vaccines (or treatment vaccines) are vaccines that are given to individuals who are already infected with a disease such as HIV. Rather than trying to prevent the illness, the vaccine is intended to help control the …

Read the full story »
[ by | Mar 28, 2012 11:00 am | One Comment ]
Researchers Make Progress In Learning How To Activate Latent HIV (CROI 2012)

A review of several recent clinical advances indicates that researchers are making progress in finding methods to activate latent HIV. Results also confirm that activating dormant HIV to render it susceptible to antiretrovirals may represent a viable strategy to reduce latent infection.

“Some interventions that have already been tested have been relatively well tolerated,” said Dr. Sharon Lewin, director of the Infectious Disease Unit at Alfred Hospital in Melbourne, Australia, and author of the review.

Dr. Lewin noted that results so far are promising but still preliminary.

“Perhaps some very …

Read the full story »
[ by | Mar 23, 2012 9:51 am | Comments Off ]
Disulfiram May Not Significantly Reduce Latent HIV Reservoirs In People With HIV (CROI 2012)

Preliminary results from an ongoing small study suggest that disulfiram, a drug used to treat alcoholism that has recently been investigated as a latent HIV activator, is safe and well tolerated. However, the results also showed that disulfiram may not significantly reduce the size of the latent HIV reservoir in HIV-positive adults taking antiretrovirals.

“There was a slight increase in viral load but it does not reach statistical significance,” said Dr. Adam Spivak, from the University of Utah School of Medicine and one of the study investigators.

“We did see …

Read the full story »